A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence. Cancers (Basel) 2023 May 17;15(10)
Date
06/22/2023Pubmed ID
37345129Pubmed Central ID
PMC10216313DOI
10.3390/cancers15102791Scopus ID
2-s2.0-85160713805 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Primary liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Conventional therapies offer limited survival benefit despite improvements in locoregional liver-directed therapies, which highlights the underlying complexity of liver cancers. This review explores the latest research in primary liver cancer therapies, focusing on developments in genomics, molecular biomarkers, and artificial intelligence. Attention is also given to ongoing research and future directions of immunotherapy and locoregional therapies of primary liver cancers.
Author List
Moroney J, Trivella J, George B, White SBAuthors
Ben George MD Professor in the Medicine department at Medical College of WisconsinJuan Pablo Trivella MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Sarah B. White MD, MS, FSIR, FCIRSE Associate Dean, Vice Chair, Professor in the Radiology department at Medical College of Wisconsin
